omeprazole has been researched along with Digestive System Diseases in 9 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Digestive System Diseases: Diseases in any part of the GASTROINTESTINAL TRACT or the accessory organs (LIVER; BILIARY TRACT; PANCREAS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion in a dose-dependent manner via inhibition of H+/K+-adenosine triphosphatase in gastric parietal cells." | 2.41 | An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole. ( Bown, RL, 2002) |
| " Dosage and treatment duration were evaluated, along with the way in which morbidity, self-evaluated health, the demographic pattern and life-style characteristics influence drug prescription." | 1.30 | Antacid (A02A) and antiulcer (A02B) drug prescription patterns: predicting factors, dosage and treatment duration. ( Girbes Pelechano, VJ; Llopis-González, A; Morales Suárez-Varela, MM; Pérez-Benajas, MA, 1998) |
| "Treatment with omeprazole also gave faster and more pronounced pain relief." | 1.27 | Clinical perspectives of drugs inhibiting acid secretion--H+K+-ATPase inhibitors. ( Walan, A, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Varallo, FR | 1 |
| de Nadai, TR | 1 |
| de Oliveira, ARA | 1 |
| Mastroianni, PC | 1 |
| Polinkevych, BS | 1 |
| Pikas, PB | 1 |
| Grinevich, VB | 1 |
| Uspenskiĭ, IuP | 1 |
| Ashley, SW | 1 |
| Cheung, LY | 1 |
| Morales Suárez-Varela, MM | 1 |
| Pérez-Benajas, MA | 1 |
| Girbes Pelechano, VJ | 1 |
| Llopis-González, A | 1 |
| Bown, RL | 1 |
| Walan, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Prophylactic Use of Omeprazole in Patients Admitted to the State Hospital of Américo Brasiliense[NCT02278432] | 427 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for omeprazole and Digestive System Diseases
| Article | Year |
|---|---|
[The role of Helicobacter pylori in occurrence of the digestive system pathologic processes].
Topics: Anti-Bacterial Agents; Digestive System Diseases; Drug Therapy, Combination; Gastric Mucosa; Helicob | 2014 |
[Secretolytic therapy of acid-dependent diseases of the digestive system from the point of view of a clinician].
Topics: Anti-Ulcer Agents; Digestive System Diseases; Gastric Acid; Humans; Hydrogen-Ion Concentration; Omep | 2003 |
Lansoprazole--another proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Digestive System Diseases; Humans; Lansoprazole; Omeprazole | 1995 |
An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Digestive System Diseases; Duodenal Ulcer; Dyspepsia; Enzym | 2002 |
1 trial available for omeprazole and Digestive System Diseases
| Article | Year |
|---|---|
Lansoprazole--another proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Digestive System Diseases; Humans; Lansoprazole; Omeprazole | 1995 |
5 other studies available for omeprazole and Digestive System Diseases
| Article | Year |
|---|---|
Potential Adverse Drug Events and Nephrotoxicity Related to Prophylaxis With Omeprazole for Digestive Disorders: A Prospective Cohort Study.
Topics: Aged; Creatinine; Digestive System Diseases; Double-Blind Method; Female; Humans; Kidney Diseases; M | 2018 |
The SSAT-AGA (Society for Surgery of the Alimentary Tract-American Gastroenterological Association). New Orleans, May 20-23, 1984.
Topics: Animals; Benzimidazoles; Colitis, Ulcerative; Colon; Common Bile Duct; Crohn Disease; Digestive Syst | 1984 |
Antacid (A02A) and antiulcer (A02B) drug prescription patterns: predicting factors, dosage and treatment duration.
Topics: Adolescent; Adult; Age Distribution; Aged; Aluminum Hydroxide; Analysis of Variance; Antacids; Anti- | 1998 |
Acid-related diseases: improving the treatment options. Symposium proceedings. Vienna, November 1991.
Topics: Animals; Digestive System Diseases; Humans; Omeprazole | 1992 |
Clinical perspectives of drugs inhibiting acid secretion--H+K+-ATPase inhibitors.
Topics: Adenosine Triphosphatases; Digestive System Diseases; Duodenal Ulcer; Esophagitis, Peptic; Gastric A | 1986 |